Today's Daily Dose brings you news about encouraging results of Cassava's Alzheimer's trial; FDA approval of DURECT's post-operative pain relief depot product, Posimir, Immunovant pausing IMVT-1401 trials and Travere's pivotal study of Sparsentan in focal segmental glomerulosclerosis yielding positive results.
Today's Daily Dose brings you news about encouraging results of Novavax' Covid-19 vaccine candidate; FDA lifting the clinical hold on Bellicum's BPX-601 study; and near-term catalysts of Ayala Pharma and AzurRx.
Today's Daily Dose brings you news about Applied Genetic's Achromatopsia trial results; the deadlock in AstraZeneca vaccine supply in EU; partnership of Lilly, Vir Biotech and GlaxoSmithKline in fighting COVID-19; and ZymeWork's progress with ZW49 study.
The small-cap biotech, CEL-SCI Corporation (NYSEMKT:CVM) has more than doubled in value in the day on record volume with ~16.3x of the 65-day average daily volume of shares changing...
CEL-SCI Corporation today issued a letter to its shareholders.
Dear Fellow Shareholders:
Happy new year to all of you. As we embark on 2021, I feel it is important to reach out to you to review... | January 4, 2021